Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers

Clinical Lung Cancer

Volumn 13, Issue 6, 2012, Pages 488-493

  Shien, Kazuhiko ^a   Ueno, Tsuyoshi ^a   Tsukuda, Kazunori ^a   Soh, Junichi ^a   Suda, Kenichi ^b   Kubo, Takafumi ^a   Furukawa, Masashi ^a   Muraoka, Takayuki ^a   Maki, Yuho ^a   Tanaka, Norimitsu ^a   Yamamoto, Hiromasa ^a   Kiura, Katsuyuki ^c   Mitsudomi, Tetsuya ^b   Toyooka, Shinichi ^a   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Epidermal growth factor receptor; Epidermal growth factor receptor tyrosine kinase inhibitors; Non small cell lung cancer; Oncogene addiction; Small interfering RNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; SMALL INTERFERING RNA AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

EID: 84867604691     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.02.003     Document Type: Article

References (27)

1. F. Ciardiello, F. De Vita, M. Orditura The role of EGFR inhibitors in nonsmall cell lung cancer Curr Opin Oncol 16 2004 130 135
2. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
3. J.G. Paez, P.A. Jänne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
4. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
5. J.W. Neal, R.S. Heist, P. Fidias Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy J Thorac Oncol 5 2010 1855 1858
6. J. Schlessinger Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672
7. N. Kobayashi, S. Toyooka, J. Soh The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor Lung Cancer 75 2012 161 166
8. J. Gandhi, J. Zhang, Y. Xie Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines PLoS ONE 4 2009 e4576
9. T. Kubo, H. Yamamoto, W.W. Lockwood MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors Int J Cancer 124 2009 1778 1784
10. A. Ogino, H. Kitao, S. Hirano Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line Cancer Res 67 2007 7807 7814
11. K. Suda, I. Murakami, T. Katayama Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer Clin Cancer Res 16 2010 5489 5498
12. T. Kubo, S. Toyooka, K. Tsukuda Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma Clin Cancer Res 17 2011 4965 4974
13. A.F. Gazdar, H. Shigematsu, J. Herz Mutations and addiction to EGFR: the Achilles "heal" of lung cancers? Trends Mol Med 10 2004 481 486
14. S. Toyooka, T. Mitsudomi, J. Soh Molecular oncology of lung cancer Gen Thorac Cardiovasc Surg 59 2011 527 537
15. K.D. Carey, A.J. Garton, M.S. Romero Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib Cancer Res 66 2006 8163 8171
16. C.H. Yun, T.J. Boggon, Y. Li Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227
17. C.H. Yun, K.E. Mengwasser, A.V. Toms The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci U S A 105 2008 2070 2075
18. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
19. W. Pao, V.A. Miller, K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
20. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
21. J. Bean, C. Brennan, J.Y. Shih MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 2007 20932 20937
22. H. Lin, J. Jiang, X. Liang Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis Lung Cancer 70 2010 57 62
23. D. Li, L. Ambrogio, T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
24. V.A. Miller, V. Hirsh, J. Cadranel Phase IIb/III double-blind randomized trial of afatinib (BIBW2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1) Ann Oncol 21 suppl 8 2010 viii1 viii12 (abstract LBA1)
25. A. Guo, J. Villén, J. Kornhauser Signaling networks assembled by oncogenic EGFR and c-Met Proc Natl Acad Sci U S A 105 2008 692 697
26. H. Yamamoto, H. Shigematsu, M. Nomura PIK3CA mutations and copy number gains in human lung cancers Cancer Res 68 2008 6913 6921
27. E. Forgacs, E.J. Biesterveld, Y. Sekido Mutation analysis of the PTEN/MMAC1 gene in lung cancer Oncogene 17 1998 1557 1565